Zhao N, Gong T Y, Wei Z C, Cong J, Liu Z H, Chen H Y
Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2024 Feb 23;46(2):99-107. doi: 10.3760/cma.j.cn112152-20231026-00257.
To explore the function and mechanism of transcription factor En1 in esophageal squamous cell carcinoma (ESCC). The correlations of En1 with prognosis were analyzed using the overall survival data of 9 397 pan-cancer patients and progression-free survival data of 4 349 pan-cancer patients from The Cancer Genome Atlas (TCGA) database. The En1 expression data in 53 and 155 cases of ESCC and their paired adjacent tissues were from Gene Expression Omnibus (GEO) database and National Genomics Data Center-Genome Sequence Archive(NGDC-GSA)database. Lentivirus was used to generate En1 stable knockout cell lines KYSE180 and KYSE450. The proliferation ability of the cells was detected by cell counting kit 8 and clone formation assay. The migration ability of the cells was detected by Transwell assay. The effect of En1 on the proliferation of ESCC was detected by xenograft experiment in BALB/c-nu/nu mice. Real-time fluorescence quantitative polymerase chain reaction (RT-qPCR) was used to detect the expressions of En1, glioma-associated oncogene family zinc finger 1 (GLI1), glioma-associated oncogene family zinc finger 2 (GLI2) and smoothened (SMO). Pan-cancer data from TCGA showed that patients with low En1 expression had longer overall survival and progression-free survival than patients with high En1 expression (< 0.001). Data from GEO and GSA databases also showed a high expression level of En1 in ESCC tissues compared with paired tissues (<0.001). Proliferation was inhibited after knockout of En1 in KYSE180 and KYSE450 cells (<0.001). The colony formation numbers decreased. The colony formation numbers of KYSE180 cells in the shEn1#1 group and the shEn1#2 group were 138.33±23.07 and 127.00±19.70, respectively, significantly lower than that of the shNC group 340.67±12.06 (<0.001). The colony formation numbers of KYSE450 cells in the shEn1#1 group and the shEn1#2 group were 65.33±2.52 and 9.00±3.00, respectively, significantly lower than that of the shNC group 139.00±13.00 (<0.001). The migration numbers was inhibited after knockout of En1 [the Transwell numbers of KYSE180 cells in the shEn1#1 group and the shEn1#2 group were 66.67±12.66 and 71.33±11.02, respectively, significantly lower than that of the shNC group 334.67±16.56 (<0.001). The Transwell numbers of KYSE450 cells in the shEn1#1 group and the shEn1#2 group were 112.33±14.57 and 54.33±5.51, respectively, significantly lower than that of the shNC group 253.33±21.03 (<0.001)]. Xenograft model showed a slower growth rate of shEn1#1 and shEn1#2 cell lines (<0.001). The tumor weights of KYSE450 cells in the shEn1#1 group and the shEn1#2 group were (0.046±0.026)g and (0.047±0.025)g, respectively, significantly lower than that of the shNC group (0.130±0.038)g (<0.001). After knockdown of En1, the relative expression levels of GLI1 in KYSE180 cells of the shEn1#1 group and the shEn1#2 group were 0.326±0.162 and 0.322±0.133, and the relative expression levels of GLI1 in KYSE450 cells of the shEn1#1 and shEn1#2 groups were 0.131±0.006 and 0.352±0.050, respectively, which were all lower than that in the shNC group (<0.01). After knockdown of En1, overexpression of GLI1 attenuated the inhibitory effect of knockdown of En1 on cell proliferation (<0.001), colony formation[the colony formation numbers of the shEn1#1-GLI1 group were 151.00±9.54, higher than 102.33±10.02 (=0.004) of the shEn1#1-vector group] and migration [the migration numbers of the shEn1#1-GLI1 group were 193.67±10.07, higher than 109.33±11.50 (0.001) in the shEn1#1-vector group]. In clinical samples of ESCC, major regulatory factors of the Hedgehog pathway were up-regulated and the pathway was activated. En1 promotes the proliferation and migration of ESCC cells by regulating the Hedgehog pathway and can be used as a new potential target for targeted therapy of ESCC.
探讨转录因子En1在食管鳞状细胞癌(ESCC)中的作用及机制。利用来自癌症基因组图谱(TCGA)数据库的9397例泛癌患者的总生存数据和4349例泛癌患者的无进展生存数据,分析En1与预后的相关性。ESCC 53例和155例及其配对癌旁组织的En1表达数据来自基因表达综合数据库(GEO)和国家基因组数据中心-基因组序列档案库(NGDC-GSA)数据库。采用慢病毒构建En1稳定敲除的KYSE180和KYSE450细胞系。通过细胞计数试剂盒8和克隆形成实验检测细胞增殖能力。采用Transwell实验检测细胞迁移能力。通过在BALB/c-nu/nu小鼠体内进行异种移植实验,检测En1对ESCC增殖的影响。采用实时荧光定量聚合酶链反应(RT-qPCR)检测En1、胶质瘤相关癌基因家族锌指蛋白1(GLI1)、胶质瘤相关癌基因家族锌指蛋白2(GLI2)和 smoothened(SMO)的表达。TCGA的泛癌数据显示,En1低表达患者的总生存期和无进展生存期均长于En1高表达患者(<0.001)。GEO和GSA数据库的数据也显示,与配对组织相比,ESCC组织中En1表达水平较高(<0.001)。敲除KYSE180和KYSE450细胞中的En1后,细胞增殖受到抑制(<0.001),集落形成数量减少。shEn1#1组和shEn1#2组KYSE180细胞的集落形成数量分别为138.33±23.07和127.00±19.70,显著低于shNC组的340.67±12.06(<0.001)。shEn1#1组和shEn1#2组KYSE450细胞的集落形成数量分别为65.33±2.52和9.00±3.00,显著低于shNC组的139.00±13.00(<0.001)。敲除En1后,细胞迁移数量受到抑制[shEn1#1组和shEn1#2组KYSE180细胞的Transwell迁移数量分别为66.67±12.66和71.33±11.02,显著低于shNC组的334.67±16.56(<0.001)。shEn1#1组和shEn1#2组KYSE450细胞的Transwell迁移数量分别为112.33±14.57和54.33±5.51,显著低于shNC组的253.33±21.03(<0.001)]。异种移植模型显示,shEn1#1和shEn1#2细胞系的生长速度较慢(<0.001)。shEn1#1组和shEn1#2组KYSE450细胞的肿瘤重量分别为(0.046±0.026)g和(0.047±0.025)g,显著低于shNC组的(0.130±0.038)g(<0.001)。敲低En1后,shEn1#1组和shEn1#2组KYSE180细胞中GLI1的相对表达水平分别为0.326±0.162和0.322±0.133,shEn1#1组和shEn1#2组KYSE450细胞中GLI1的相对表达水平分别为0.131±0.006和0.352±0.050,均低于shNC组(<0.01)。敲低En1后,过表达GLI1可减弱敲低En1对细胞增殖的抑制作用(<0.001)、集落形成[shEn1#1-GLI1组的集落形成数量为151.00±9·54,高于shEn1#1-载体组的102.33±10.02(=0.004)]和迁移[shEn1#1-GLI1组的迁移数量为193.67±10.07,高于shEn1#1-载体组的109.33±11.50(0.001)]。在ESCC临床样本中,Hedgehog信号通路的主要调控因子上调,该信号通路被激活。En1通过调控Hedgehog信号通路促进ESCC细胞的增殖和迁移,可作为ESCC靶向治疗的新潜在靶点。